Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Jun 19, 2040compositionUS 11613511
Jun 19, 2040formulationUS 11760714
Jun 19, 2040method-of-use (U-3873)US 11926584
Jun 19, 2040compositionUS 12398087
Jun 19, 2040compositionUS 12404227
Mar 14, 2036method-of-use (U-3224)US 10912751
Mar 14, 2036method-of-use (U-3692)US 11744816
Dec 3, 2030compositionUS 73357994.3y

FDA exclusivities (2)

Mar 22, 2027I-943Indication (3y)215d
Mar 22, 2027I-945Indication (3y)215d

News(0)

no news has mentioned this drug yet

brand

Nexlizet

generic

(bempedoic acid + ezetimibe)

MOA

12.1 Mechanism of Action NEXLIZET contains bempedoic acid and ezetimibe. NEXLIZET reduces elevated LDL-C through inhibition of cholesterol synthesis in the liver and absorption in the intestine. Bempedoic acid Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors. Ezetimibe Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in LDL receptors, resulting in clearance of cholesterol from the blood.

indication

Heterozygous Familial Hypercholesterolemia (heFH)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 4m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

(bempedoic acid + ezetimibe)

Marketedupdated 3mo ago

by $ESPR Esperion Therapeutics, Inc.

Approved

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

indications

investigational

Hyperlipidemia

all catalysts(9)

approval · 9

NEXLIZET (BEMPEDOIC ACID) — FDA approval

(bempedoic acid + ezetimibe)

NEXLIZET (BEMPEDOIC ACID) — FDA approval

(bempedoic acid + ezetimibe)

NEXLIZET (BEMPEDOIC ACID) — FDA approval

(bempedoic acid + ezetimibe)

NEXLIZET (BEMPEDOIC ACID) — FDA approval

(bempedoic acid + ezetimibe)

NEXLIZET (BEMPEDOIC ACID) — FDA approval

(bempedoic acid + ezetimibe)

NEXLIZET (BEMPEDOIC ACID) — FDA approval

(bempedoic acid + ezetimibe)

NEXLIZET (BEMPEDOIC ACID) — FDA approval

(bempedoic acid + ezetimibe)

NEXLIZET (BEMPEDOIC ACID) — FDA approval

(bempedoic acid + ezetimibe)

NEXLIZET (BEMPEDOIC ACID) — FDA approval

(bempedoic acid + ezetimibe)

→

view all 9 catalysts →

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 22, 2027

215 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Jun 19, 2040compositionUS 11613511
Jun 19, 2040formulationUS 11760714
Jun 19, 2040method-of-use (U-3873)US 11926584
Jun 19, 2040compositionUS 12398087
Jun 19, 2040compositionUS 12404227
Mar 14, 2036method-of-use (U-3224)US 10912751
Mar 14, 2036method-of-use (U-3692)US 11744816
Dec 3, 2030compositionUS 73357994.3y

FDA exclusivities (2)

Mar 22, 2027I-943Indication (3y)215d
Mar 22, 2027I-945Indication (3y)215d

News(0)

no news has mentioned this drug yet

brand

Nexlizet

generic

(bempedoic acid + ezetimibe)

MOA

indication

Heterozygous Familial Hypercholesterolemia (heFH)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 4m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

(bempedoic acid + ezetimibe)

🐶 often sniffed alongside

indications

all catalysts(9)

Patent cliff

patents (8)

FDA exclusivities (2)

News(0)

Report a data issue

comments(0)

(bempedoic acid + ezetimibe)

🐶 often sniffed alongside

indications

all catalysts(9)

Patent cliff

patents (8)

FDA exclusivities (2)

News(0)

Report a data issue

comments(0)